Clinical Trial

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Protocol Amendment History 4 changes
notable Enrollment increased: 117 -> 190 participants 2026-08-11
minor Trial arms changed: 1 -> 2 2026-08-11
notable Trial sites expanded: 17 -> 22 locations 2026-07-08
notable Trial sites expanded: 13 -> 17 locations 2026-06-23
Trial Details
NCT Number NCT06823167
Lead Sponsor Immunome, Inc.
Conditions Solid Malignancies, Hematologic Malignancies
Enrollment 190 participants
Start Date 2025-02-26
Primary Completion 2028-05 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-10